# US 2025/0084158 A1 · Anti-cll-1 antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084158 A1
- Document ID: US20250084158A1
- Status: Published application
- Kind: A1
- Application number: 18/580,552
- Filed: 2022-07-20
- Published: 2025-03-13
- Earliest claimed: 2021-07-20
- Assignees: Abl Bio Inc.
- Applicants: Abl Bio Inc.
- Inventors: Eunsil SUNG; Junga KWON; Youngkwang KIM; Juhee KIM; Kyungjin PARK; Sumyeong PARK; Byungje SUNG; Byeongmin YOO; Bora LEE; Suyoun LEE; Shinai LEE; Yangsoon LEE; Eunhee LEE; Yangmi LIM; Jaehyoung JEON; Jinwon JUNG
- Web page: https://patentgrep.com/patent/US20250084158A1

## CPC

- C07K 16/24: against cytokines, lymphokines or interferons
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6877: {the antibody being an immunoglobulin containing regions, domains or residues from different species}
- A61K 47/6879: {the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin}
- A61P 35/00: Antineoplastic agents
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are anti-CLL-1 antibodies and uses thereof, according to the anti-CLL-1 antibody of one aspect, it can bind to CLL-1 with high binding affinity, and can cause activation of T cells, thus it can be used effectively for preventing or treating the cancer expressing CLL-1.

## Claims

### Claim 1

An isolated anti-CLL-1 antibody or an antigen-binding fragment thereof comprising:
(a) a VH CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2 and 3;
(b) a VH CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5 and 6;
(c) a VH CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 7, 8, 9, 10 and 11;
(d) a VL CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 13, 14 and 15;
(e) a VL CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 17 and 18; and
(f) a VL CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 19, 20, 21 and 22.

### Claim 2 (depends on 1)

The anti-CLL-1 antibody of claim 1,
wherein the anti-CLL-1 antibody or fragment thereof comprises a heavy chain constant region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 23 and 24.

### Claim 3 (depends on 1)

The anti-CLL-1 antibody of claim 1,
wherein the anti-CLL-1 antibody or fragment thereof comprises a light chain constant region comprising an amino acid sequence consisting of SEQ ID NO: 55.

### Claim 4 (depends on 1)

The anti-CLL-1 antibody of claim 1,
wherein the anti-CLL-1 antibody or fragment thereof comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 and 74.

### Claim 5 (depends on 1)

The anti-CLL-1 antibody of claim 1,
wherein the anti-CLL-1 antibody or fragment thereof comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 36, 37, 38, 39, 40, 41, 42, 43, 44 and 75.

### Claim 6 (depends on 1)

The anti-CLL-1 antibody of claim 1,
wherein the anti-CLL-1 antibody or fragment thereof comprises a heavy chain comprising an amino acid sequence consisting of SEQ ID NO: 45.

### Claim 7 (depends on 14)

The anti-CLL-1 antibody of claim 14
wherein the anti-CLL-1 antibody or fragment thereof comprises a light chain comprising an amino acid sequence consisting of SEQ ID NO: 46.

### Claim 8 (depends on 1)

The anti-CLL-1 antibody of claim 1,
wherein the anti-CLL-1 antibody or fragment thereof comprises the sequence of CDRH1, CDRH2 and CDRH3 of the heavy chain variable region and CDRL1, CDRL2 and CDRL3 of the light chain variable region is any one of the followings:
(a) CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 1, 4, and 7, respectively, and CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 12, 16 and 19, respectively;
(b) CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 2, 5, and 8, respectively, and CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 13, 17 and 20, respectively;
(c) CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 3, 6, and 9, respectively, and CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 14, 18 and 21, respectively;
(d) CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 1, 4, and 10, respectively, and CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 15, 16 and 22, respectively; and
(e) CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 2, 5, and 11, respectively, and CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 13, 17 and 20, respectively.

### Claim 9 (depends on 1)

The anti-CLL-1 antibody of claim 1,
wherein the anti-CLL-1 antibody or antigen-binding fragment thereof is a mouse antibody, a chimeric antibody, a humanized antibody, or a fully human antibody.

### Claim 10 (depends on 1)

The anti-CLL-1 antibody of claim 1,
wherein the anti-CLL-1 antibody or antigen-binding fragment thereof is selected from a group consisting of a whole IgG, Fab, Fab′, F(ab′)2, xFab, scFab, dsFv, Fv, scFv, scFv-Fc, scFab-Fc, diabody, minibody, scAb, dAb, half-IgG and combinations thereof.

### Claim 11 (depends on 1)

The anti-CLL-1 antibody of claim 1,
which is in the form of IgG1.

### Claim 12 (depends on 1)

The anti-CLL-1 antibody of claim 1,
wherein the anti-CLL-1 antibody or antigen-binding fragment thereof is Fab molecule.

### Claim 13 (depends on 1)

The anti-CLL-1 antibody of claim 1, wherein the anti-CLL-1 antibody or antigen-binding fragment has one or more of the following characteristics:
(a) binds to human CLL-1;
(b) binds to cynomolgus monkey CLL-1;
(c) binds to CLL-1 on the surface of human peripheral blood mononucleocytes (PBMCs);
(d) binds to CLL-1 on the surface of cynomolgus monkey PBMCs; and
(e) binds to CLL-1 on the surface of a cancer cell.

### Claim 14 (depends on 1)

The anti-CLL-1 antibody of claim 1,
a cytotoxic agent is conjugated to at least portion of the anti-CLL-1 antibody or antigen-binding fragment.

### Claim 15 (depends on 14)

The anti-CLL-1 antibody of claim 14,
wherein the cytotoxic agent is attached to the anti-CLL-1 antibody or antigen-binding fragment through the linker.

### Claim 16 (depends on 15)

The anti-CLL-1 antibody of claim 15,
wherein the linker is cleavable by a protease.

### Claim at position 17

17-18. (canceled)

### Claim 19 (depends on 1)

An immunoconjugate comprising a formula Ab-(L-D)p, wherein: (a) Ab is the anti-CLL-1 antibody of claim 1; (b) L is a linker; (c) D is a cytotoxic agent; and (d) p ranges from 1 to 8.

### Claim 20 (depends on 1)

An isolated nucleic acid encoding the anti-CLL-1 antibody of claim 1.

### Claim 21 (depends on 1)

A method for treating or preventing a cancer in a patient in need thereof, comprising administering to the patient an effective amount of the anti-CLL-1 antibody of claim 1.

### Claim at position 21

22-24. (canceled)

### Claim 25 (depends on 21)

The method of claim 21, wherein the cancer is a cancer expressing CLL-1.

### Claim 26 (depends on 21)

The method of claim 21,
wherein the cancer is selected from the group consisting of leukemia, rectal cancer, endometrial cancer, nephroblastoma, basal cell carcinoma, nasopharyngeal cancer, bone tumor, esophageal cancer, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, follicular thyroid cancer, hepatocellular carcinoma, oral cancer, renal cell carcinoma, multiple myeloma, mesothelioma, osteosarcoma, myelodysplastic syndrome, mesenchymal tumor, soft tissue sarcoma, liposarcoma, gastrointestinal stromal tumor, malignant peripheral nerve sheath tumor (MPNST), ewing sarcoma, leiomyosarcoma, mesenchymal chondrosarcoma, lymphosarcoma, fibrosarcoma, rhabdomyosarcoma, teratoma, neuroblastoma, medulloblastoma, glioma, benign skin tumor, Burkitt's lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma (DLBCL), follicular lymphoma, marginal zone lymphoma, neuroectodermal tumor, epithelial tumor, cutaneous T-cell lymphoma (CTCL), peripheral T cell lymphoma (PTCL), pancreas cancer, haematological malignancies, kidney cancer, tumor vasculature, breast cancer, renal cancer, ovarian cancer, epithelial ovarian cancer, gastric cancer, liver cancer, lung cancer, colorectal cancer, pancreatic cancer, skin cancer, bladder cancer, testicular cancer, uterine cancer, prostate cancer, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), neuroblastoma, brain cancer, colon cancer, squamous cell carcinoma, melanoma, myeloma, cervical cancer, thyroid cancer, head and neck cancer and adrenal cancer.

### Claim at position 24

27-29. (canceled)
